Blood Glucose Threshold for Holding Glipizide

Primary Threshold: 70 mg/dL (3.9 mmol/L)

The American Diabetes Association defines Level 1 hypoglycemia as blood glucose <70 mg/dL (3.9 mmol/L), which is the critical threshold for counterregulatory hormone release and represents clinically important hypoglycemia regardless of symptoms 1, 2, 4
Glipizide should be withheld at this threshold because sulfonylureas stimulate insulin secretion independent of glucose levels, creating substantial risk for progression to Level 2 hypoglycemia (<54 mg/dL) where neuroglycopenic symptoms occur 1
This 70 mg/dL cutoff is specifically designated as the "hypoglycemia alert value" requiring therapeutic dose adjustment of glucose-lowering drugs in clinical care 4

For hospitalized patients or those with limited caloric intake, consider holding glipizide when blood glucose falls below 100 mg/dL (5.6 mmol/L) to provide a safety margin 5
Hospitalized patients require insulin regimen reassessment when glucose drops below 100 mg/dL to prevent hypoglycemia 5

Before each glipizide dose, check blood glucose - never rely on symptoms alone to determine hypoglycemia status 1, 2
If glucose <70 mg/dL (3.9 mmol/L), hold glipizide dose and treat hypoglycemia with 15-20 g fast-acting carbohydrate 1, 2
If glucose 70-100 mg/dL in high-risk patients, hold glipizide dose and provide food first, then reassess need for medication 5

Use the 100 mg/dL threshold for holding glipizide in patients with renal impairment, hepatic disease, elderly patients, hypoglycemia unawareness, sepsis or acute illness 3, 5
The American Diabetes Association recommends considering the 100 mg/dL threshold for patients with hypoglycemia unawareness, as they are at increased risk of severe hypoglycemia 1, 2

Never administer glipizide when blood glucose is already in the hypoglycemic range (<70 mg/dL), as sulfonylureas have a duration of action extending 12-24 hours and will continue driving insulin secretion 1, 2
Level 2 hypoglycemia (<54 mg/dL) triggers neuroglycopenic symptoms including confusion, seizures, and loss of consciousness 1, 2
Severe hypoglycemia (Level 3) causes cognitive impairment requiring external assistance and can result in significant morbidity or mortality 1, 3